|
Return
to main press room
page
FOR IMMEDIATE RELEASE
Francis P. Tally, M.D., Appointed to
Therion
Biologics Board of Directors
Cambridge, MA, July 31, 1997 - Therion Biologics
Corporation announced today that Francis P. Tally,
M.D., Vice President of Drug Development and
Medical Affairs at Cubist Pharmaceuticals, has been
appointed to its Board of Directors. Dr. Tally
brings to Therion more than 24 years of experience
in academia and the pharmaceutical industry. He
becomes the fifth member of Therion's Board.
"Dr. Tally's breadth of pharmaceutical expertise,
which spans clinical development and drug
discovery, will augment the current strengths of
our Board," said Dennis L. Panicali, Ph.D.,
President and Chief Executive Officer of Therion
Biologics. "His guidance will be particularly
valuable as we advance the development of our
therapeutic cancer vaccines and our preventive AIDS
vaccines."
Prior to joining Cubist, Dr. Tally served at
Lederle Laboratories of American Cyanamid/American
Home Products as Executive Director of Infectious
Disease, Molecular Biology and Natural Products
Research. At Lederle, Dr. Tally was responsible for
worldwide clinical studies for
piperacillin/tazobactam (Zosyn®), directed
discovery research in infectious disease, and was
responsible for developing two new classes of
antibiotics. Previously, he was Senior Pathologist
and Senior Physician at New England Medical Center,
and Associate Professor of Pathology and Medicine
at Tufts University School of Medicine. Dr. Tally
received his A.B. in Biology from Providence
College, and his M.D. from George Washington
University School of Medicine.
Therion Biologics Corporation is engaged in the
development of immunotherapeutic products and
vaccines for the treatment of major cancers and the
prevention of AIDS. Therion is headquartered in
Cambridge, Massachusetts.
|
Contacts:
Dennis L. Panicali, Ph.D.
President and CEO
Therion Biologics Corporation
(617) 876-7779
|
Kelly Overly, Ph.D.
Manager
Feinstein Kean Healthcare Inc
(617) 577-8110
|
###
Back to
the top
|
|
